• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Keppra
    / CTS


    Active Ingredient
    Levetiracetam 250, 500, 1000 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    60 X 250 mg

    partial basket chart 69504 11203

    Film Coated Tablets

    60 X 500 mg

    partial basket chart 63356 11192

    Film Coated Tablets

    60 X 1000 mg

    partial basket chart 63357 11193

    Related information


    Dosage

    The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food.
    Keppra tablets should not be chewed or crushed.
    The tablet formulation is not adapted for use in infants and children under the age of 6 years.
    See prescribing information for full details.


    Indications

    For adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy.As adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. As monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy. Treatment of primary generalized tonic-clonic seizures (PGTCS) in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.


    Contra-Indications

    Hypersensitivty to levetiracetam or other pyrrolidone derivatives or any of the excipients.


    Special Precautions

    If discontinued, withdraw gradually (e.g. 500 mg 2 x daily decrements every 2-4 weeks.) Administration to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.
    Pregnancy and lactation: Should not be used during pregnancy unless clearly necessary. Discontinuation of antiepileptic treatments may result in worsening of disease, harmful to the mother and fetus. Breast-feeding is not recommended. Caution is recommended when performing skilled tasks, e.g. driving vehicles and operating machinery.


    Side Effects

    Very common: Asthenia, somnolence.
    Common: Amnesia, ataxia, convulsion, dizziness, headache, tremor. Depression, emotional lability, hostility, insomnia, nervousness. Diarrhea, dyspepsia, nausea, anorexia, vertigo. Diplopia, accidental injury, rash.


    Manufacturer
    UCB S.A., Belgium
    Licence holder
    CLOSE